Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
News|Articles|July 12, 2016
EMA Determines Benefits of Zydelig Outweigh Risks
Author(s)Pharmaceutical Technology Editors
The agency completes its risk assessment of the blood cancer treatments.
Advertisement
The European Medicines Agency (EMA) has completed its review of the blood cancer treatment Zydelig (idelalisib) and determined that the benefits outweigh the risks. The agency’s Pharmacovigilance Risk Assessment Committee (PRAC) reviewed the treatment following a high rate of serious adverse events associated with the drug. PRAC did determine that there is a risk of serious infections with use of the medication, including Pneumocystis jirovecii pneumonia.
EMA states that, “the risk of serious infection is considered relevant to the authorized use and the PRAC recommends that all patients treated with Zydelig should be given antibiotics to prevent Pneumocystis jirovecii pneumonia during treatment and for up to 2 to 6 months after treatment has stopped. Patients should also be monitored for infection and have regular blood tests for white cell counts because low counts can increase their risk of infection. Zydelig should also not be started in patients with a generalized infection.”
Zydelig (idelalisib) is used, in combination with rituximab, for the treatment of chronic lymphocytic leukaemia (CLL) in patients who have received previous treatment. It is also used to treat “previously untreated patients who have certain genetic mutations in their cancer cells (17p deletion or TP53 mutation) that make them unsuitable for treatment with a combination of chemotherapy medicines and immunotherapy (treatments that stimulate the immune system to kill cancer cells)," according to EMA. Zydelig (idelalisib) is also authorized in the European Union for the treatment of a type of non-Hodgkin’s lymphoma called follicular lymphoma.
Source:
Advertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement